VOR - Vor Biopharma Inc.
IEX Last Trade
0.8351
0.012 1.437%
Share volume: 920
Last Updated: Thu 26 Dec 2024 08:07:41 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.82
0.01
1.46%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
0.74%
1 Month
9.31%
3 Months
18.98%
6 Months
-23.96%
1 Year
-65.16%
2 Year
-86.10%
Key data
Stock price
$0.84
DAY RANGE
$0.82 - $0.85
52 WEEK RANGE
$0.68 - $2.64
52 WEEK CHANGE
-$66.37
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Bob Ang
Region: US
Website: vorbio.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vorbio.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Recent news